DOI QR코드

DOI QR Code

Midface Infection after COVID-19 Vaccination in a Patient with Calcium Hydroxylapatite Dermal Filler: A Case Report and Literature Review

  • Jeon, Hong Bae (Department of Plastic and Reconstructive Surgery, Dankook University Hospital) ;
  • Yoon, Jae Hee (Department of Plastic and Reconstructive Surgery, Dankook University Hospital) ;
  • Lim, Nam Kyu (Department of Plastic and Reconstructive Surgery, Dankook University Hospital)
  • Published : 2022.05.15

Abstract

The emergence of vaccines for coronavirus disease 2019 (COVID-19) raises risk of possible adverse events from interaction between the vaccines and facial aesthetic care. A 47-year-old female with no medical comorbidities visited our emergency room due to midface painful swelling after 3 hours following receiving the second dose of the messenger RNA BNT162b2 COVID-19 vaccine. About 14 years ago, she underwent nonsurgical augmentation on the nasojugal groove with a calcium hydroxylapatite dermal filler. We performed incision and drainage under general anesthesia on the next day. During operation, yellowish pus-like materials bulged out. After an operation, we performed a combination therapy with antibiotics and methylprednisolone. Her symptoms improved day by day after surgery, and then a complete recovery was achieved at 3 weeks after the treatment. In conclusion, providers of aesthetic procedures are to be aware of the potential risks of such vaccines for patients who already had or seek to receive dermal filler injections.

Keywords

References

  1. Nayak LM. Commentary on "Coronavirus Vaccine Considerations for the Aesthetic Patient" by Rice et al.-Our Duty to Our Patients. Facial Plast Surg Aesthet Med 2021;23(02):76-77 https://doi.org/10.1089/fpsam.2021.0014
  2. Gotkin RH, Gout U, Sattler S, et al. Global recommendations on COVID-19 vaccines and soft tissue filler reactions: a survey-based investigation in cooperation with the International Society for Dermatologic and Aesthetic Surgery (ISDS). J Drugs Dermatol 2021;20(04):374-378 https://doi.org/10.36849/JDD.6041
  3. Michon A. Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination - a case report. J Cosmet Dermatol 2021;20(09):2684-2690 https://doi.org/10.1111/jocd.14312
  4. Rowland-Warmann MJ. Hypersensitivity reaction to hyaluronic acid dermal filler following novel coronavirus infection - a case report. J Cosmet Dermatol 2021;20(05):1557-1562 https://doi.org/10.1111/jocd.14074
  5. Munavalli GG, Guthridge R, Knutsen-Larson S, Brodsky A, Matthew E, Landau M. "COVID-19/SARS-CoV-2 virus spike proteinrelated delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment". Arch Dermatol Res 2022;314(01):1-15 https://doi.org/10.1007/s00403-021-02190-6
  6. Ghasemi S, Dashti M. Fight against COVID-19 with mRNA vaccines and interaction with dermal fillers. Clin Exp Vaccine Res 2021;10(02):151-153 https://doi.org/10.7774/cevr.2021.10.2.151
  7. Pau M, Reinbacher KE, Feichtinger M, Navysany K, Karcher H. The mandibular symphysis as a starting point for the occlusal-level reconstruction of panfacial fractures with bicondylar fractures and interruption of the maxillary and mandibular arches: report of two cases. J Craniomaxillofac Surg 2014;42(04):e51-e56 https://doi.org/10.1016/j.jcms.2013.06.002
  8. Owczarczyk-Saczonek A, Zdanowska N, Wygonowska E, Placek W. The Immunogenicity of hyaluronic fillers and its consequences. Clin Cosmet Investig Dermatol 2021;14:921-934 https://doi.org/10.2147/CCID.S316352
  9. Jansen DA, Graivier MH. Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006;118(3, Suppl):22S-30S https://doi.org/10.1097/01.prs.0000234903.55310.6a
  10. Munavalli GG, Knutsen-Larson S, Lupo MP, Geronemus RG. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angio-tensin II-induced cutaneous inflammation. JAAD Case Rep 2021;10:63-68 https://doi.org/10.1016/j.jdcr.2021.02.018